- Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.
- Natera, Genentech, and NRG Oncology are involved in cancer diagnostics/treatment, specifically Natera's Signatera test in the ARCHER trial.
Natera plans commercial launch in Japan by end of 2026 after the PMDA approved its Signatera test for colorectal cancer.
5 reports, 2 independent
Updated Oct 19
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Natera plans commercial launch in Japan by end of 2026 after the PMDA approved its Signatera test for colorectal cancer.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Natera receives FDA Breakthrough Device designation for its assay.1 source
PMDA approved Signatera test for colorectal cancer; Natera plans commercial launch in Japan by end of 2026.1 source
Keep exploring
The entities involved
-
Natera
company in San Carlos, United States
-
Pharmaceuticals and Medical Devices Agency
administrative agency in Japan
Nothing else this week.